Science

Frozen in action: Visualizing how a cancer drug scaffold is built

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 19/10/2026, 15:10:24 UTC.

Briefings

A joint research team led by Ryo Tanifuji, Hiroki Oguri, and Yoshikazu Tanaka from the University of Tokyo and Tohoku University successfully visualized the enzymatic assembly of SacC, an enzyme critical for constructing the five-ring core of safracin B. This core structure is structurally conserved in trabectedin, a therapeutic agent targeting soft tissue sarcoma. The study provides a mechanistic insight into the biosynthesis pathway of this complex molecule.

Key points

• The enzyme SacC was visualized by a joint research group led by Ryo Tanifuji, Hiroki Oguri, and Yoshikazu Tanaka from the University of Tokyo and Tohoku University.
• SacC is an enzyme responsible for building the five-ring core of safracin B, a structure shared with trabectedin used to treat soft tissue sarcoma.

Context

Understanding the enzymatic assembly of safracin B is crucial for developing targeted therapies for soft tissue sarcoma, as the enzyme's mechanism mirrors that of trabectedin.

Limitations

The evidence is limited to a single research group's visualization of SacC's role in safracin B core formation. No data on the specific reaction kinetics, intermediate structures, or clinical trial outcomes for trabectedin are provided.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 19/10/2026, 15:11:28 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihz3i2d77f6ewvs264exspn3nfmraw3g3lifto6nh44f6maddg6vq